source
- Deerfield-backed Boulevard Bio embarks on ‘beautiful path to a cure’ with trio of immunology drugsBoulevard Bio has strolled out of stealth with $65 million in funding from Deerfield Management and three autoimmune disease candidates.Fierce Biotech · 1d ago↗ source
- FDA issues early alert after BD needle set defects linked to four deathsThe FDA’s Center for Devices and Radiological Health released an early alert warning clinicians to stop using Becton Dickinson’s intraosseous vascular access needle sets after reports of serious in…